Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock

In the last three months, 7 analysts have published ratings on Lexicon Pharmaceuticals (NASDAQ:LXRX), offering a diverse range of perspectives from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	7	0	0	0	0
Last 30D	1	0	0	0	0
1M Ago	2	0	0	0	0
2M Ago	3	0	0	0	0
3M Ago	1	0	0	0	0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.0, a high estimate of $10.00, and a low estimate of $10.00. No alteration is observed as the current average remains at the previous average price target.

Understanding Analyst Ratings: A Comprehensive Breakdown

The standing of Lexicon Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00
Joseph Pantginis	HC Wainwright & Co.	Maintains	Buy	$10.00	$10.00

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lexicon Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lexicon Pharmaceuticals compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Lexicon Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

To gain a panoramic view of Lexicon Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Lexicon Pharmaceuticals analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.

Lexicon Pharmaceuticals: A Financial Overview

Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.

Revenue Growth: Lexicon Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 419.56%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Lexicon Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -3244.02%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -20.21%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Lexicon Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.52%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Lexicon Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 0.42. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

Understanding the Relevance of Analyst Ratings

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.